Schmidt P J Investment Management Inc. Sells 236 Shares of Johnson & Johnson $JNJ

Schmidt P J Investment Management Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,659 shares of the company’s stock after selling 236 shares during the period. Schmidt P J Investment Management Inc.’s holdings in Johnson & Johnson were worth $2,392,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in JNJ. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Wealth Group Ltd. bought a new position in Johnson & Johnson during the 1st quarter valued at about $218,000. Motiv8 Investments LLC grew its holdings in Johnson & Johnson by 6.6% during the 1st quarter. Motiv8 Investments LLC now owns 9,164 shares of the company’s stock valued at $1,520,000 after purchasing an additional 564 shares during the last quarter. PDS Planning Inc grew its holdings in Johnson & Johnson by 9.3% during the 1st quarter. PDS Planning Inc now owns 18,586 shares of the company’s stock valued at $3,082,000 after purchasing an additional 1,589 shares during the last quarter. Finally, Perpetual Ltd grew its holdings in Johnson & Johnson by 27.2% during the 1st quarter. Perpetual Ltd now owns 41,288 shares of the company’s stock valued at $6,847,000 after purchasing an additional 8,830 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 15th. Citigroup upped their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, October 15th. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Barclays boosted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 10th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $190.38 on Monday. The stock has a market cap of $458.69 billion, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The firm has a 50-day moving average of $182.26 and a two-hundred day moving average of $166.37.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.